Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company focused on advancing imaging-based products for breast cancer care, has announced the integration of its proprietary AI-based machine-learning reconstruction algorithm into its flagship IzoView Breast CT Imaging System. This development, achieved in collaboration with The Johns Hopkins University School of Medicine, aims to significantly improve image quality while ensuring low radiation doses are maintained.
The algorithm represents a notable advancement over conventional denoising methods such as Model-Based Iterative Reconstruction (MBIR) and Deep Machine-Learning Reconstruction (DMLR), which are often constrained by limitations in speed and workflow practicality. By addressing image noise at its source, Izotropic's innovative approach offers a potential breakthrough for enhancing clinical efficiency in breast cancer screening protocols. This integration could lead to more accurate diagnoses and streamlined imaging processes in medical facilities.
For additional details, the full press release is available at https://ibn.fm/znaoJ. More information about Izotropic Corporation can be found on its website at https://izocorp.com and by reviewing its profile on SEDAR at https://sedarplus.ca. The latest news and updates relating to IZOZF are available in the company’s newsroom at https://ibn.fm/IZOZF.
This advancement holds implications for the broader medical imaging and oncology sectors, potentially setting a new standard for AI integration in diagnostic equipment. Improved image quality with maintained low radiation could enhance patient safety and diagnostic accuracy, benefiting healthcare providers and patients globally. The collaboration with a prestigious institution like Johns Hopkins University underscores the technical credibility and potential impact of this development on future breast cancer screening technologies.
